Immune checkpoint inhibitors targeting programmed cell death protein 1 and programmed death ligand-1, such as atezolizumab, pembrolizumab and nivolumab, significantly improve OS in patients with advanced NSCLC compared with chemotherapy (20–23). Here, PDCD1 is linked to non-small cell lung carcinoma.